Financhill
Sell
29

NURO Quote, Financials, Valuation and Earnings

Last price:
$3.82
Seasonality move :
-6.74%
Day range:
$3.80 - $4.01
52-week range:
$2.66 - $4.73
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.81x
P/B ratio:
0.50x
Volume:
28.1K
Avg. volume:
23.8K
1-year change:
14.2%
Market cap:
$8M
Revenue:
$5.9M
EPS (TTM):
-$4.24

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
NURO
NeuroMetrix
-- -- -- -- --
CATX
Perspective Therapeutics
$237.9K -$0.20 -- -70.12% --
ECOR
electroCore
$6.7M -- 35.84% -- $27.47
RVP
Retractable Technologies
-- -- -- -- --
VTAK
Catheter Precision
$290K -$2.60 118.75% -11.57% --
XTNT
Xtant Medical Holdings
$29.3M -$0.02 11.16% -33.33% --
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
NURO
NeuroMetrix
$3.90 -- $8M -- $0.00 0% 1.81x
CATX
Perspective Therapeutics
$2.85 -- $192.6M -- $0.00 0% 15.39x
ECOR
electroCore
$15.14 $27.47 $99.2M -- $0.00 0% 4.60x
RVP
Retractable Technologies
$0.64 -- $19.2M -- $0.00 0% 0.50x
VTAK
Catheter Precision
$0.33 -- $2.6M 0.38x $0.00 0% 0.88x
XTNT
Xtant Medical Holdings
$0.36 -- $50M -- $0.00 0% 0.42x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
NURO
NeuroMetrix
-- 0.663 -- 12.38x
CATX
Perspective Therapeutics
-- -5.312 -- --
ECOR
electroCore
-- -2.426 -- 1.71x
RVP
Retractable Technologies
1.55% 0.611 11.72% 5.80x
VTAK
Catheter Precision
12% -11.532 128.21% 0.53x
XTNT
Xtant Medical Holdings
43.2% 1.226 37.09% 0.81x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
NURO
NeuroMetrix
$312K -$1.7M -41.7% -41.7% -296.61% -$1.8M
CATX
Perspective Therapeutics
-- -$18.6M -- -- -- -$26.3M
ECOR
electroCore
$5.5M -$2.7M -144.52% -144.52% -40.45% -$1.4M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
VTAK
Catheter Precision
$86K -$2.9M -63.93% -65.84% -4258.33% -$2.8M
XTNT
Xtant Medical Holdings
$16.3M -$3.8M -22.96% -35.98% -13.47% -$3.8M

NeuroMetrix vs. Competitors

  • Which has Higher Returns NURO or CATX?

    Perspective Therapeutics has a net margin of -256.8% compared to NeuroMetrix's net margin of --. NeuroMetrix's return on equity of -41.7% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    CATX
    Perspective Therapeutics
    -- -$0.21 --
  • What do Analysts Say About NURO or CATX?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10156.41%. On the other hand Perspective Therapeutics has an analysts' consensus of -- which suggests that it could grow by 466.67%. Given that NeuroMetrix has higher upside potential than Perspective Therapeutics, analysts believe NeuroMetrix is more attractive than Perspective Therapeutics.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    CATX
    Perspective Therapeutics
    0 0 0
  • Is NURO or CATX More Risky?

    NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.129, suggesting its more volatile than the S&P 500 by 12.894%.

  • Which is a Better Dividend Stock NURO or CATX?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or CATX?

    NeuroMetrix quarterly revenues are $587.3K, which are larger than Perspective Therapeutics quarterly revenues of --. NeuroMetrix's net income of -$1.5M is higher than Perspective Therapeutics's net income of -$15.1M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.81x versus 15.39x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    1.81x -- $587.3K -$1.5M
    CATX
    Perspective Therapeutics
    15.39x -- -- -$15.1M
  • Which has Higher Returns NURO or ECOR?

    electroCore has a net margin of -256.8% compared to NeuroMetrix's net margin of -38.1%. NeuroMetrix's return on equity of -41.7% beat electroCore's return on equity of -144.52%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    ECOR
    electroCore
    83.75% -$0.31 $9.5M
  • What do Analysts Say About NURO or ECOR?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10156.41%. On the other hand electroCore has an analysts' consensus of $27.47 which suggests that it could grow by 81.44%. Given that NeuroMetrix has higher upside potential than electroCore, analysts believe NeuroMetrix is more attractive than electroCore.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    ECOR
    electroCore
    3 0 0
  • Is NURO or ECOR More Risky?

    NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison electroCore has a beta of 0.574, suggesting its less volatile than the S&P 500 by 42.566%.

  • Which is a Better Dividend Stock NURO or ECOR?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. electroCore offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. electroCore pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or ECOR?

    NeuroMetrix quarterly revenues are $587.3K, which are smaller than electroCore quarterly revenues of $6.6M. NeuroMetrix's net income of -$1.5M is higher than electroCore's net income of -$2.5M. Notably, NeuroMetrix's price-to-earnings ratio is -- while electroCore's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.81x versus 4.60x for electroCore. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    1.81x -- $587.3K -$1.5M
    ECOR
    electroCore
    4.60x -- $6.6M -$2.5M
  • Which has Higher Returns NURO or RVP?

    Retractable Technologies has a net margin of -256.8% compared to NeuroMetrix's net margin of -18.58%. NeuroMetrix's return on equity of -41.7% beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About NURO or RVP?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10156.41%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that NeuroMetrix has higher upside potential than Retractable Technologies, analysts believe NeuroMetrix is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    RVP
    Retractable Technologies
    0 0 0
  • Is NURO or RVP More Risky?

    NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Retractable Technologies has a beta of 1.979, suggesting its more volatile than the S&P 500 by 97.877%.

  • Which is a Better Dividend Stock NURO or RVP?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Retractable Technologies pays out -3.32% of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or RVP?

    NeuroMetrix quarterly revenues are $587.3K, which are smaller than Retractable Technologies quarterly revenues of $10.3M. NeuroMetrix's net income of -$1.5M is higher than Retractable Technologies's net income of -$1.9M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.81x versus 0.50x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    1.81x -- $587.3K -$1.5M
    RVP
    Retractable Technologies
    0.50x -- $10.3M -$1.9M
  • Which has Higher Returns NURO or VTAK?

    Catheter Precision has a net margin of -256.8% compared to NeuroMetrix's net margin of -4291.67%. NeuroMetrix's return on equity of -41.7% beat Catheter Precision's return on equity of -65.84%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    VTAK
    Catheter Precision
    89.58% -$2.01 $14.6M
  • What do Analysts Say About NURO or VTAK?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10156.41%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 506.06%. Given that NeuroMetrix has higher upside potential than Catheter Precision, analysts believe NeuroMetrix is more attractive than Catheter Precision.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    VTAK
    Catheter Precision
    0 0 0
  • Is NURO or VTAK More Risky?

    NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.210, suggesting its less volatile than the S&P 500 by 121.025%.

  • Which is a Better Dividend Stock NURO or VTAK?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or VTAK?

    NeuroMetrix quarterly revenues are $587.3K, which are larger than Catheter Precision quarterly revenues of $96K. NeuroMetrix's net income of -$1.5M is higher than Catheter Precision's net income of -$4.1M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Catheter Precision's PE ratio is 0.38x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.81x versus 0.88x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    1.81x -- $587.3K -$1.5M
    VTAK
    Catheter Precision
    0.88x 0.38x $96K -$4.1M
  • Which has Higher Returns NURO or XTNT?

    Xtant Medical Holdings has a net margin of -256.8% compared to NeuroMetrix's net margin of -17.98%. NeuroMetrix's return on equity of -41.7% beat Xtant Medical Holdings's return on equity of -35.98%.

    Company Gross Margin Earnings Per Share Invested Capital
    NURO
    NeuroMetrix
    53.12% -$0.75 $16M
    XTNT
    Xtant Medical Holdings
    58.37% -$0.04 $80.5M
  • What do Analysts Say About NURO or XTNT?

    NeuroMetrix has a consensus price target of --, signalling upside risk potential of 10156.41%. On the other hand Xtant Medical Holdings has an analysts' consensus of -- which suggests that it could grow by 525%. Given that NeuroMetrix has higher upside potential than Xtant Medical Holdings, analysts believe NeuroMetrix is more attractive than Xtant Medical Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    NURO
    NeuroMetrix
    0 0 0
    XTNT
    Xtant Medical Holdings
    0 0 0
  • Is NURO or XTNT More Risky?

    NeuroMetrix has a beta of 2.182, which suggesting that the stock is 118.234% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of 0.357, suggesting its less volatile than the S&P 500 by 64.342%.

  • Which is a Better Dividend Stock NURO or XTNT?

    NeuroMetrix has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NeuroMetrix pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios NURO or XTNT?

    NeuroMetrix quarterly revenues are $587.3K, which are smaller than Xtant Medical Holdings quarterly revenues of $27.9M. NeuroMetrix's net income of -$1.5M is higher than Xtant Medical Holdings's net income of -$5M. Notably, NeuroMetrix's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NeuroMetrix is 1.81x versus 0.42x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    NURO
    NeuroMetrix
    1.81x -- $587.3K -$1.5M
    XTNT
    Xtant Medical Holdings
    0.42x -- $27.9M -$5M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret

It’s not often that a company with the scale and…

Will Tyson Foods Stock Bounce Back?
Will Tyson Foods Stock Bounce Back?

Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…

Will Iovance Biotherapeutics Stock Bounce Back?
Will Iovance Biotherapeutics Stock Bounce Back?

Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.3T
P/E Ratio: 113x

Buy
55
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 37x

Alerts

Buy
61
QMCO alert for Dec 23

Quantum [QMCO] is down 0.92% over the past day.

Sell
46
NUKK alert for Dec 23

Nukkleus [NUKK] is up 7.95% over the past day.

Sell
1
IIPR alert for Dec 23

Innovative Industrial Properties [IIPR] is down 5.91% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock